Sensus Healthcare, Inc. (SRTS) ended the recent trading session at $5.48, demonstrating a -0.54% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.18%, while the tech-heavy Nasdaq appreciated by 0.35%. Heading into today, shares of the company had gained 4.16% over the past month, outpacing the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25% in that time. Analysts and investors alike will ...

财务数据和关键指标变化 - 第一季度收入同比增长超过3倍,达到1.07亿美元,主要由于本季度发货26台设备,而去年同期为10台 [34] - 毛利率从去年同期的47.5%提升至62.5% [35] - 净利润为230万美元,而去年同期为亏损190万美元 [39] - 调整后EBITDA从去年同期的-270万美元转为300万美元 [40] - 现金和现金等价物从去年年底的2.31亿美元下降至1.47亿美元,主要用于备货 [41] - 应收账款从去年年底的1.06亿美元增加至1.96亿美元,但大部分已经收回 [41] - 存货从去年年底的1.19亿美元增加至1.47亿美元,以应对价格上涨和预期需求增长 [42] 各条业务线数据和关键指标变化 - 影像导航型SRT-100 Vision系统是公司的主要产品,在行业内拥有领先地位和专利技术 [15][20][22] - 公司推出了新的"公平交易协议"销售模式,为客户提供更灵活的购买选择 [11][17][19] - 公司正在等待FDA对TransDermal Infusion(TDI)产品的510(k)申请的审批结果 [24][25] 各个市场数据和关键指标变化 - 公司在2023年新进入了爱尔兰、危地马拉和土耳其等3个国际市场 [29] - 在亚洲市场,公司首次在台湾销售了SRT-100 Vision系统给台湾一家大型私立医院 [29] - 公司还首次在以色列的一家领先宠物医院销售了SRT-100系统,用于治疗宠物肿瘤 [30] - 公司计划在未来每年新进入2-3个国际市场 [31] 公司战略和发展方向及行业竞争 - 公司专注于皮肤科市场,同时也在与放射肿瘤科医院进行接触 [23] - 公司与CureRays合作,为客户提供监管和指导,提高SRT治疗的效率和有效性 [21] - 公司正在研究SRT在炎症性疾病等新适应症的应用 [21] - 公司认为SRT将成为非黑色素瘤皮肤癌的首选治疗方式 [47][48] - 公司的新销售模式和技术优势有助于进一步扩大市场份额 [10][17][20] 管理层对经营环境和未来前景的评论 - 公司在过去几年经历了疫情和通胀等挑战,但现已重拾强劲增长势头 [46] - 公司看好SRT在非黑色素瘤皮肤癌和瘢痕疙瘩治疗中的巨大市场机会 [47][48][49] - 公司有信心未来会取得成功,并拥有出色的团队来推动增长和实施战略 [49] 问答环节重要的提问和回答 问题1 **Yi Chen 提问** 历史上第四季度通常是最强的季度,但今年第一季度的表现已经接近历史第四季度水平,未来其他季度的表现会如何? [52] **Joe Sardano 回答** 第一季度的强劲表现为全年奠定了良好基础,第二季度有望保持同样的强劲势头。第三季度通常较为淡季,第四季度则可能受到选举等因素的影响而表现谨慎。但公司仍然期待第四季度能够保持良好表现。[53][54][55][56] 问题2 **Yi Chen 提问** "公平交易协议"是否是第一季度表现的主要驱动因素? [57] **Joe Sardano 回答** "公平交易协议"并非主要驱动因素,但它反映了公司未来的发展方向。该模式正在引起越来越多的关注和兴趣,预计未来会带来更多订单。预计到明年下半年和2026年,这一业务线会带来更显著的收入贡献。[58][59] 问题3 **Anthony Vendetti 提问** 公司最大客户在本季度的订单占比是否超过50%? [67] **Joe Sardano 回答** 是的,公司最大客户在本季度的订单占比超过50%。这家客户在全国范围内都有广泛的业务布局。[72][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State ...

Exhibit 99.1 Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold · Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarter · Launched the “Fair Deal Agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State or ot ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Conference Call February 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA, IR Joe Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Chen - H.C. Wainwright Anthony Vendetti - Maxim Group Ben Haynor - Alliance Global Partners Operator Good day and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2023 Financial Results Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State or other jurisdiction ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Kim Sutton Golodetz - LHA, IR Joe Sardano - Chairman & CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Alex Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Good afternoon and welcome to the Sensus Healthcare Third Quarter 2023 Financial Results Conference Call. All ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to _____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State ...

Sensus Healthcare, Inc (NASDAQ:SRTS) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Kim Golodetz - IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Ben Haynor - Alliance Global Partners Operator Welcome to the Sensus Healthcare Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being ...